Key Developments For Bio-Reference Laboratories, Inc.
Bio-Reference Laboratories, Inc. (BRLI.O) (Nasdaq)
Bio-Reference Laboratories, Inc. (BRLI) Announces Award Of New York State Department Of Corrections Laboratory Services Contract
Bio-Reference Laboratories, Inc. (BRLI) announced that State of New York Department of Correctional Services has once again selected BRLI to be the Department's provider of Statewide Laboratory Services. Pursuant to its internal requirements, the Department submits its contract for laboratory services for bid and proposal every five years. The State first went to a unified statewide contract for laboratory services in 1998 and since that time BRLI has continuously been the provider of laboratory services. Over the next five years, BRLI indicated that it expects revenues from this Contract to exceed $35M.
Practice Fusion and Bio-Reference Laboratories, Inc. Team To Offer Free Electronic Health Records To Physicians
Practice Fusion Inc. announced a partnership with Bio-Reference Laboratories, Inc. The companies will collaborate to distribute Practice Fusion's EHR to interested BioReference physicians and will integrate BioReference lab results into the Practice Fusion's system.
Bio-Reference Laboratories, Inc. (BRLI) Reaffirms FY 2009 Outlook
Bio-Reference Laboratories, Inc. (BRLI) announced that for fiscal 2009, it reaffirmed the guidance that sees at least a 15% increase in the top-line revenues and a 20% increase in the net income. The Company reported revenue of $301.07 million and net income of $15.62 million in fiscal 2008. According to Reuters Estimates, analysts are expecting the Company to report net income of $18.7 million for fiscal 2009.
Bio-Reference Laboratories, Inc. (BRLI) Announces NextGen Sequencing for Dilated Cardiomyopathy Testing
Bio-Reference Laboratories, Inc. (BRLI) announced that it is offering next generation sequencing testing for Dilated Cardiomyopathy (DCM) conditions through its GeneDx laboratory. After nearly two years of development, GeneDx has designed software that enables the laboratory to provide focused, multi-gene diagnostic analysis of complex cases spanning multiple genes. GeneDx first pioneered the use of this platform previously with its test for Hypertrophic Cardiomyopathy (HCM), which it began offering in September 2008.
Bio-Reference Laboratories, Inc. (BRLI) Comments On FY 2009 Guidance
Bio-Reference Laboratories, Inc. (BRLI) announced that for fiscal 2009, it expects top-line revenue to grow at least 15% and that its net income will increase at least 20%. According to Reuters Estimates, analysts were expecting the Company to report revenue of $339.10 million and net income of $19.42 million for fiscal 2009.
